Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lemborexant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 known ✓ | O43613 | 20/20 | 1.00 |
| ▸ | HCRTR2 known ✓ | O43614 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lemborexant SCHEMBL19866794 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Lemborexant SCHEMBL29521503 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Lemborexant SCHEMBL15202534 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Lemborexant SCHEMBL2116558 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Lemborexant SCHEMBL30181455 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2KCNH2 | |
| Lemborexant SCHEMBL31393500 | 0.95 | HCRTR1 (0.91) | HCRTR1HCRTR2KCNH2 | |
| Lemborexant SCHEMBL31367627 | 0.95 | HCRTR1 (0.91) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2610668 | 0.94 | HCRTR1 (0.89) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2610608 | 0.94 | HCRTR1 (0.89) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2619079 | 0.93 | HCRTR1 (0.87) | HCRTR1HCRTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190201399-A1 | COMPOSITIONS AND METHODS FOR TREATING INSOMNIA | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201399-A1 | COMPOSITIONS AND METHODS FOR TREATING INSOMNIA | HCRTR2, HCRTR1, CNR2 | HCRTR1 2/4885HCRTR2 1/4885KCNH2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.